Clinical trials: Neurogenic Detrusor Overactivity
Overactive Bladder, Urinary Urge Incontinence
Over Active Bladder Instillation Study - Botox
The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly…
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia
- Trial name
- NCT00667095
- Testing
- Botox Instillation, DMSO Instillation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Neurogenic Detrusor Overactivity
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity
This is a prospective, multicentre (7 sites), randomized, double-blind, study comparing intravesical injection of BOTOX to placebo in 56 subjects with NDO secondary to spinal cord injury or multiple sclerosis.
- Trial name
- NCT01091727
- Testing
- Botulinum toxin A
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- Sunnybrook Health Sciences Centre
Neurogenic Detrusor Overactivity, Pediatric
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
- Trial name
- NCT01981954
- Testing
- Solifenacin succinate
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Spinal Cord Injuries, Neuromodulation
Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury
The investigators will recruit up to 20 volunteers with chronic, supra-sacral SCI. Following screening, eligible participants will enter 'Phase I', they will complete baseline outcome measures and then have the epidural spinal…
- Conditions
- Spinal Cord Injuries, Neuromodulation, Neurogenic Bladder, Neurogenic Bowel
- Trial name
- ImPRESS (NCT06515223)
- Testing
- Epidural Spinal Cord Stimulation
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Spinal Cord Injury, Acute
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure.
- Trial name
- TASCI (NCT03965299)
- Testing
- VERUM TTNS
- Where
- 4 sites in Switzerland
- Volunteers
- 114 people
- Sponsor
- University of Zurich
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.
- Trial name
- NCT02601287
- Testing
- Botulinum Toxin Type A
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Allergan
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan
Mild Cognitive Impairment, Spinal Cord Injuries
Effects of Antimuscarinics on Cognition in Spinal Cord Injury
Prospective evaluation of the cognitive function of in-house patients suffering from an acute traumatic spinal cord injury before and three months after the initiation of antimuscarinic treatment.
- Trial name
- NCT01600404
- Testing
- antimuscarinic treatment
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Swiss Paraplegic Research, Nottwil
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Autonomic Dysreflexia
Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI
The purpose of this study is to investigate the impact of 200 U intradetrusor injected OnabotulinumtoxinA (Botox®, Allergan, Inc.) (20 sites, trigone sparing) for neurogenic detrusor overactivity (NDO) and its role on reducing…
- Trial name
- NCT02298660
- Testing
- BOTOX
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- Rick Hansen Institute
Urinary Bladder Neurogenic Dysfunction
Neuro-urological Outcome After Spinal Cord Injury
Most patients with spinal cord injury suffer from bladder dysfunction which may - especially in the long-term - impair renal function. Improved treatment during the last decades improved life expectancy and quality of life.
- Trial name
- NCT01297660
- Testing
- Video-urodynamic examination
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- Balgrist University Hospital
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Spinal Cord Injury, Detrusor Overacitivity
Effects of Sacral and Tibial Stimulation on Bladder Function in Subacute Suprasacral Spinal Cord Injury
Suprasacral spinal cord injury (SCI) frequently leads to neurogenic detrusor overactivity (NDO), resulting in elevated bladder storage pressures, urinary incontinence, and an increased risk of upper urinary tract damage.
- Trial name
- NCT07343583
- Testing
- Transcutaneous Tibial Nerve Stimulation, Transcutaneous Sacral Nerve Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Ankara City Hospital Bilkent
Neurogenic Detrusor Overactivity
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).
- Trial name
- NCT03168828
- Testing
- Trospium-Releasing Intravesical System (TAR-302-5018)
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Taris Biomedical LLC
Multiple Sclerosis, Neurogenic Bladder
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
- Conditions
- Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases
- Trial name
- SONIC (NCT00629642)
- Testing
- Solifenacin Succinate, Oxybutynin Hydrochloride
- Where
- 39 sites in Australia, Belgium and 9 more
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma Inc
Spinal Dysraphism
Determining Developmental and Clinical Markers Affecting Urinary Function of Children With Spinal Dysraphism
To identify developmental and clinical biomarkers that affect urinary incontinence at the ages of 5, 7, and 10 according to different neuro-urological clinical factors.
- Trial name
- NCT05962086
- Where
- 6 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital